title: The effect of inhaled gallopamil, a potent calcium channel blocker, on the late-phase response in subjects with allergic asthma.
abstract: The effect of gallopamil on the late-phase response to inhaled allergen was evaluated in six young adults with allergic asthma in a crossover manner. During 2 study days, subjects received 20 mg of inhaled gallopamil or placebo 30 minutes before challenge with the same dose of allergen. In addition, a histamine challenge was performed 1 1/2 hours before and 24 hours after allergen challenge. On 2 additional study days, in the absence of allergen, basal airway responsiveness to histamine was measured before and after gallopamil or placebo administration. During the early phase, the mean +/- SD decrease in FEV1 was 28.0% +/- 11.3% after placebo and 25.1% +/- 8.4% after gallopamil administration (p greater than 0.05; beta = 0.14). During the late phase, the maximum decrease in FEV1 was 26.9% +/- 11.9% after placebo and 25.3% +/- 10.3% after gallopamil administration (p greater than 0.05; beta = 0.21). Airway reactivity to histamine 24 hours after allergen challenge could not be measured in three subjects after gallopamil administration and in one subject after placebo administration because of persistent bronchospasm. In contrast, basal responsiveness to histamine in the absence of allergen was modestly decreased by gallopamil. Since gallopamil is one of the most potent calcium channel blockers when it is administered by the inhaled route, it is unlikely that this group of drugs will be clinically useful for allergic asthma.
authors.affiliation: College of Pharmacy, University of Florida, Gainesville.
authors.forename: M
authors.initials: M
authors.lastname: Hoppe
authors.forename: E
authors.initials: E
authors.lastname: Harman
authors.forename: L
authors.initials: L
authors.lastname: Hendeles
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000485:Allergens; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests / Q000379:methods; D004341:Drug Evaluation; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D005711:Gallopamil / Q000008:administration & dosage*; D006632:Histamine; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D013147:Spirometry; D013997:Time Factors
chemical_list: D000485:Allergens; D005711:Gallopamil; D006632:Histamine